KMT2D, along with NCOA6 acts as a coactivator of tumor suppressors and is required for the expression of endogenous p53 target genes in response to the DNA-damaging agent to the cancer cells such as Doxorubicin (Lee et al., 2009). Here, KMT2D is linked to cancer.